The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

If Viatris could sell generic versions of Wegovy and Ozempic, it'd be a major driver of new top-line growth. Sales of Ozempic brought in more than $3 billion for Novo Nordisk in the most recent ...

The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.

Novo Nordisk's underperformance in recent weeks is attributed to a patent challenge by Viatris over its weight-loss therapy, Wegovy. Read more here.

Novo Nordisk A/S NVO successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic.. Viatris Inc VTRS, via its ...

Read here to know Viatris ... For now, NVO's Wegovy/ Ozempic and Eli Lilly's Mounjaro have been heralded as the next golden goose in the biotech/ pharmaceutical sector, ...